Company news

Ultragenyx Pharmaceutical Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ultragenyx to Participate at Investor Conferences in November

November 19, 2023

Ultragenyx to Participate in the Jefferies London Healthcare Conference

November 6, 2023

Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update

November 1, 2023

Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update

October 25, 2023

Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 22, 2023

Ultragenyx Announces Proposed Public Offering of Common Stock

October 16, 2023

Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease

October 15, 2023

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

October 13, 2023

Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

October 8, 2023

Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023

October 4, 2023

Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

September 24, 2023

Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update

August 2, 2023

Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

July 30, 2023

Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update

July 26, 2023

Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

July 11, 2023

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

July 5, 2023

Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts

June 20, 2023

Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

June 6, 2023

Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)

June 4, 2023

Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit

May 18, 2023

Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.

May 16, 2023

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting

May 7, 2023

Ultragenyx to Present at Bank of America’s 2023 Health Care Conference

May 4, 2023

Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update

May 3, 2023

Dennis Huang of Ultragenyx Named to MassBio’s Board of Directors

April 27, 2023

Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update

April 26, 2023

Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days

March 27, 2023

Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

March 13, 2023

Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference

February 27, 2023

Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

February 15, 2023

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update

February 8, 2023

Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones

January 5, 2023

Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Ultragenyx to Present at Piper Sandler Healthcare Conference

November 21, 2022

Ultragenyx Announces Departure of Chief Financial Officer

November 9, 2022

Ultragenyx to Present at Upcoming Healthcare Conferences

November 8, 2022

Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update

November 1, 2022

Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update

October 26, 2022

Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR

September 8, 2022

Ultragenyx to Participate at Citi BioPharma Conference

August 31, 2022

Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update

July 27, 2022

Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate Update

July 24, 2022

Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study

July 17, 2022

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets

July 13, 2022

Ultragenyx to Present at Goldman Sachs Global Healthcare Conference

June 9, 2022

Ultragenyx to Present at Jefferies Global Healthcare Conference

May 31, 2022

Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

May 18, 2022

Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics

May 16, 2022

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

May 8, 2022

Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update

May 4, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.